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 Glaucoma is a sight-threatening and potentially blinding
condition that affects about 70 million globally [1,2]. The mo-
lecular basis of the pathogenesis of this disease remains un-
clear. Its major risk factor, however, is ocular hypertension
due to an abnormal reduction of aqueous humor outflow. The
literature is replete with studies concerning the regulation of
aqueous outflow using a variety of agents [3]. In consequence
there has been much attention in the design of relevant mod-
els of glaucoma, which may then be used to understand the
pathogenesis of the disease and to test potential new drugs for
their ability to lower intraocular pressure (IOP). Of special
interest is the development of animal models in which spe-
cific genes known to be associated with glaucoma, for ex-
ample, myocilin mutants [4] and transforming growth factor
β2 [5], are introduced in ocular tissues.
To this end, viral vectors have been used increasingly for
the delivery of specific transgenes encoding a variety of gene
products. There are many reports describing the ocular use of
different vectors, such as adenovirus, adeno-associated virus,
herpes simplex virus, and lentivirus [6]. In particular, viral
transduction of the trabecular meshwork (TM), a structure in-
timately involved in the regulation of aqueous outflow, has
been reported with adenovirus, which exhibits both good tro-
pism for this tissue and relatively strong transgene expression
[7-10]. Moreover, ocular transduction using adenoviral vec-
tors does not produce observable untoward effects, nor does it
nonspecifically affect aqueous hydrodynamics [9]. Unfortu-
nately, however, the adenovirus-mediated transgene expres-
sion is transient and only lasts about 1 to 2 weeks [7,8], thus
limiting its usefulness as a research tool in long-term studies.
The transient nature of adenoviral expression is likely due
to an immune response generated against viral proteins and/
or transgene products [8,11,12]. Hence, various strategies have
been designed to prolong viral expression via immunosup-
pression. One of these strategies involves blockade of the bind-
ing of CD40 to CD40 ligand (CD40L, also known as CD154).
CD40 is a costimulatory protein found on antigen presenting
cells. Binding of CD40 to CD40L on T-lymphocytes leads to
activation of the antigen presenting cells and T-cells, and pro-
duces a variety of downstream effects, including both humoral
and cellular immune responses [13-15]. This interaction can
be effectively impeded by treatment with the anti-CD40L an-
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Purpose: Gene transduction using adenoviral vectors is an important research tool. To assess and optimize this technique
for glaucoma research, we characterized green fluorescent protein (GFP) expression in the mouse eye after intraocular
injection of adenoviral vector encoding GFP (Ad5.CMV-GFP) and evaluated the effect of anti-CD40L antibody adminis-
tration on GFP expression.
Methods: Mice were injected with Ad5.CMV-GFP intracamerally (IC) or intravitreally (IVT) with or without anti-CD40L
antibody treatment. GFP expression was assessed by in vivo fluorescence intensity with a standardized grading scale.
Location of expression was analyzed histologically by fluorescence microscopy.
Results: Intraocular injection of Ad5.CMV-GFP induced titer-dependent expression of GFP in the anterior segment. In
vivo fluorescence was detectable but low after IC injection. After IVT injection, fluorescence in the eye peaked at days 4-
7 with a fluorescence grade of 3.0 ±0.0 (mean ±SEM, n=6; injection with 1x108 pfu vector). After day 7, GFP expression
declined significantly. Treatment with anti-CD40L antibody increased fluorescence intensity after IC injection, and pro-
longed GFP expression in the IVT group. At day 43, fluorescence grades of the IVT group were 2.8 ±0.7 (with anti-
CD40L) and 1.2 ±0.6 (without antibody). Three-Way ANOVA confirmed that GFP expression was significantly higher in
the anti-CD40L than the no antibody group (p=0.013), significantly higher in the IVT than the IC group (p=0.003), and
significantly higher in the high viral titer (1x108 pfu) than the low titer (1x107 pfu) group (p=0.010). Fluorescence micro-
scopic examination of cross-sections of eyes indicated GFP expression in the trabecular meshwork (TM), corneal endot-
helium, and sporadically iris, ciliary body and lens epithelium.
Conclusions: Intraocular injection of Ad5.CMV-GFP induced GFP expression in the mouse anterior segment, including
the TM. Expression was more prominent after IVT injection than IC injection. Anti-CD40L antibody treatment increased
both intensity and duration of GFP expression. These findings provide important and practical means to improve duration
and efficiency of adenovirus-mediated transgene expression in the eye.
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10tibody, which has been reported to be effective as an adjunc-
tive immunomodulating agent for facilitation of organ trans-
plantation, as well as treatments for atherosclerosis, systemic
lupus erythromatosus and rheumatoid arthritis [16]. Most im-
portantly, systemic treatment of mouse with anti-CD40L anti-
body significantly extends the duration of transgene expres-
sion of recombinant adenovirus in the liver [17-19].
In this study, we characterized the expression profile and
duration of an adenoviral vector (Ad5.CMV-GFP) encoding
jellyfish (Aequorea victoria) green fluorescent protein (GFP)
after intracameral (IC) or intravitreal (IVT) injection of dif-
ferent titers. More importantly, we also determined whether
transgene expression in the mouse eye could be prolonged via
treatment with anti-CD40L antibody.
METHODS
Animal husbandry:  All animal experiments were conducted
in compliance with the ARVO Statement for the Use of Ani-
mals in Ophthalmic and Vision Research, and the Alcon Ani-
mal Care and Use Committee regulations. Adult male Balb/cJ
mice (Jackson Laboratory, Bar Harbor, ME) weighing between
20 and 30 g (three to five months of age) were used in this
study. The animals were maintained on a 12 h light/12 h dark
cycle in a temperature-controlled (22 °C) facility. Food and
water were available ad libitum.
Ad5.CMV-GFP:  Ad5.CMV-GFP was purchased from
Qbiogene (Montreal, Canada). This viral vector is a first gen-
eration (∆E1/∆E3) adenovirus serotype 5 particles expressing
the GFP gene under control of the cytomegalovirus-IE pro-
moter/enhancer. The expression of GFP can be easily moni-
tored by the green fluorescence. Therefore, it is used exten-
sively as a marker to test the infectivity of specific cells both
in vitro and in vivo.
Intraocular injection:  Mice were examined at day -1 by
direct ophthalmoscopy (Hand-Held Ophthalmoscope, Welch-
Allyn, Model 11710, Skaneateles Falls, NY) to confirm a nor-
mal appearance, free of any signs of ocular disease. At day 0,
mice were anesthetized with an intraperitoneal injection of an
anesthesia cocktail (ketamine, 73 mg/kg, Fort Dodge, IA;
xylazine, 1.8 mg/kg, Vetus, Burns Veterinary Supply, Westbury,
NY; acepromazine, 1.8 mg/kg, Vetus). The right eye (OD) of
each animal was then topically anesthetized with one to two
drops of 0.5% proparacaine (Alcaine®, Alcon Laboratories,
Fort Worth, TX) and then given a single intravitreal (IVT) or
intracameral (IC) injection of a suspension of Ad5.CMV-GFP
(1x107 pfu or 1x108 pfu in a volume of 2 µl). Eyes given IC
injection were also pretreated with one to two drops 1%
cyclopentolate (Mydriacyl®, Alcon Laboratories) to dilate the
pupil. Ocular injections were administered using a Hamilton
glass microsyringe (10 µl capacity) fitted with a custom-made
one-inch 33G needle with a 10° bevel (Hamilton, Reno, NV).
Immunomodulation:  Hamster anti-mouse CD40L anti-
body (Biosource International, Camarillo, CA) was used to
suppress immune responses by blockade of the interaction
between CD40 and CD40L. Assigned animals were injected
with this antibody (0.5 mg/mouse, intraperitoneal) on days -1,
0 (immediately preceding intraocular injection), 1, 2, 5, 9, and
14, a treatment schedule modified from that reported by Stein
et al. [18]
In vivo evaluation:  Commencing on day 4 after the in-
jection and then on following predetermined days, each in-
jected eye was examined under ultraviolet illumination
(Illumatool® Model LT-9900; Lightools Research, Encinatas,
CA) through a filter (excitation 470 nm, emission 515 nm) for
fluorescence, as an indication of presence of GFP in the ante-
rior chamber. Based on its intensity and distribution, fluores-
cence grades were assigned at the indicated days by a re-
searcher who was masked to the treatments. Throughout the
study, all eyes (injected and control) were carefully examined
with a hand-held ophthalmoscope for the presence of iridial
hyperemia and lenticular opacity. Animals were also assessed
daily for potential gross abnormalities in appearance and be-
havior by the veterinary staff.
Histological analysis:  Following assessment of fluores-
cence and ophthalmic examination on days 6 and 43, randomly
assigned animals were euthanized (CO2 asphyxiation). Both
eyes, injected and uninjected control, were enucleated and fixed
with 4% paraformaldehyde. Eyes were embedded with Opti-
mal Cutting Temperature (OCT) embedding medium and
stored at -80 °C until cryosectioned (thickness=10 µm). The
sections were evaluated by fluorescence microscopy for evi-
dence of GFP expression in various ocular tissues.
Statistical analysis:  Fluorescence grades were expressed
as mean ±SEM. Three-way ANOVA was used to analyze the
effects of injection routes, viral titers, and antibody treatment
on the integrated fluorescence grades. P values of less than
0.05 were regarded as statistically significant.
RESULTS
In vivo fluorescence grading scale:  To assess the in vivo ex-
pression of GFP, we designed a standardized, semi-quantita-
tive ordinal fluorescence grading scale based on the intensity
and diffusiveness of the observed fluorescence in the mouse
eye. This scale ranges from 0, indicating no observable fluo-
rescence, to 4, which represents brilliant fluorescence through-
out the anterior segment (Table 1). According to this grading
system, eyes of grade 0.5 or 1 had small discrete spots of barely
or readily, respectively, detectable fluorescence typically only
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TABLE 1. DEFINITIONS OF IN VIVO FLUORESCENCE ORDINAL GRADING
SCALE
This standardized semi-quantitative grading scale was used to assess
the in vivo expression of GFP in the anterior segment of mouse eyes.
11in the region of the chamber angle. Eyes of grades 2 and 3
expressed GFP in a much larger portion of the chamber angle
as well as other structures of the anterior segment. Figure 1
demonstrates images of representative eyes with the respec-
tive grades.
Expression of GFP: in vivo observations:  Intraocular in-
jections, both IC and IVT, of Ad5.CMV-GFP induced produc-
tion of GFP and hence fluorescence in the anterior segment of
the mouse eye. The intensity and duration of GFP expression
were dependent on the injection route, viral titer, and treat-
ment with antiCD40L antibody. For example, IC injection of
1x107 pfu without antibody treatment produced a barely de-
tectable fluorescence in the anterior segment (fluorescence
grade at day 5=0.06 ±0.06, mean ±SEM, n=9; Figure 2A).
Whereas, increasing the injected viral titer to 1x108 pfu boosted
GFP expression to a higher level (Fluorescence Grade at day
5=0.83 ±0.38, n=9; Figure 2B). Interestingly, when Ad5.CMV-
GFP was injected intravitreally, the expression of GFP in the
anterior segment was clearly higher than when it was injected
intracamerally. Specifically, IVT injection of Ad5.CMV-GFP
at 1x107 pfu produced a peak fluorescence intensity at days 4-
7, with a fluorescence grade at day 5 of 2.00 ±0.00 (n=6; Fig-
ure 2C and Figure 3). Similar to IC injection, IVT injection of
the viral vector at a higher titer (1x108 pfu) generated higher
fluorescence expression (fluorescence grade at day 5=3.00
±0.00 [n=6; Figure 2D and Figure 3]). The effect in the IVT
groups however began to diminish starting at day 7. By day
30 fluorescence had almost disappeared in both the IC and
IVT groups injected with the lower titer (1x107 pfu) of
Ad5.CMV-GFP (Figure 2).
Regardless of injection routes or titers of Ad5.CMV-GFP
used, immunomodulation with treatment of anti-CD40L anti-
body always enhanced GFP expression in the mouse eye. Af-
ter IC injections, anti-CD40L antibody treated animals showed
an increase in fluorescence intensities. For example, the fluo-
rescence grade at day 5 of Ad5.CMV-GFP (1x 107 pfu)-trans-
fected eyes increased to 0.44 ±0.36, while that of 1x108 pfu-
injected eyes increased to 1.36 ±0.48. The elevated fluores-
cence persisted or was further raised slightly until at least day
43 (Figure 2). The anti-CD40L antibody did not significantly
affect the peak fluorescence level in the IVT group, such that
the fluorescence grades at day 5 of eyes injected intravitreally
with either 1x 107 pfu or 1x108 pfu did not differ with or with-
out antibody treatment. However, antibody treatment dramati-
cally lengthened the duration of GFP expression in these ani-
mals. Without anti-CD40L antibody, IVT injection of 1x107
pfu Ad5.CMV-GFP produced a fluorescence grade of 0.17
±0.18 at day 43. Antibody treatment augmented that to 1.66
±0.61 (Figure 2C). Likewise, anti-CD40L antibody improved
fluorescence grade at day 43 from 1.17 ±0.59 to 2.83 ±0.72 in
the 1x108 pfu group (Figure 2D). Representative images at
day 35 of intravitreally injected mice are shown in Figure 4.
The effects of injection routes, viral titers, and antibody
treatment on ocular GFP fluorescence can be summarized by
the integrated fluorescence grades. These values were obtained
by integrating the area under the “Fluorescence Grade” ver-
sus “Time” curve of each animal. As seen in Figure 2E, it is
obvious that the integrated fluorescence grade was affected
by the injection route, viral titer injected, and the use of anti-
CD40L antibody. This observation was confirmed by analysis
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Figure 1. Representative
examples of mouse eyes
with various fluorescence
grades.  The number un-
der each image indicates
the assigned grade. Defi-
nitions of the grades are
listed in Table 1.
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Figure 2. Effects of routes of intraocular injections, titers of viral vector, and use of anti-CD40L antibody on the intensity and duration of GFP
expression evaluated by in vivo fluorescence grades.  At day 0, Ad5.CMV-GFP, at a titer of 1x107 pfu (A and C) or 1x08 pfu (B and D), was
injected intracamerally (A and B) or intravitreally (C and D) with (open symbols) or without (closed symbols) immunomodulation by intrap-
eritoneal treatment of anti-CD40L antibody. In vivo fluorescence in the eyes was evaluated and fluorescence grades assigned at the indicated
days by a researcher who was masked of the treatments. The fluorescence grades were further analyzed as the integrated fluorescence (E) by
summation of the area under the curve of each animal. All data were presented as mean and SEM.
13of the data with three-way ANOVA, which indicated that GFP
expression was significantly higher in the anti-CD40L than
the no antibody group (p=0.013), significantly higher in the
IVT than the IC group (p=0.003), and significantly higher in
the high viral titer (1x108 pfu) than the low titer (1x107 pfu)
group (p=0.010). Furthermore, there was no statistically sig-
nificant (p>0.05) interaction between any two or among all
three variables.
Intraocular injection of viral vectors did not cause any
abnormalities in the majority (57%) of eyes as observed by
ophthalmoscopic examination throughout the study period.
Among the vector-injected eyes, at day 6 after injection, 26%
were found to develop iridal hyperemia: 23% had slight but
detectable redness or dilation of iridal vessels, whereas 3%
displayed moderate redness of the whole iris. Lenticular opac-
ity was noted in 21% of the injected eyes: 9% had barely vis-
ible or very small discrete opacity, and 12% had opacity that
involved more than 20% of the visible area of the lens. These
untoward effects typically appeared between days 4 and 6 af-
ter injection, and persisted till end of study. There was no cor-
relation between the untoward effects and injection routes, viral
titers, antibody treatment, or fluorescence grades. None of the
treatments produced any systemic untoward effects as judged
by daily evaluation of gross appearance and behavior of the
animals.
Expression of GFP: fluorescence microscopy:  Cross-sec-
tions of mouse eyes obtained from animals euthanized at days
5 and 43 following intraocular Ad5.CMV-GFP injection were
examined by fluorescence microscopy, and GFP expression
was typically localized to the cornea, TM, iris, ciliary body,
and lens. No GFP fluorescence was detected in the retina re-
gardless of injection route. Furthermore, the observed ocular
distribution and intensity of GFP expression correlated very
well with in vivo fluorescence grades of the different groups.
For example, not much fluorescence in the anterior segment
was observed at 5 and 43 days after IC injection of 1x107 pfu
Ad5.CMV-GFP without anti-CD40L antibody treatment (Fig-
ure 5), while treatment with the anti-CD40L antibody enhanced
the expression of GFP of the same injection regimen. Under
this condition, a fraction of cells in the TM and corneal endot-
helium expressed GFP (Figure 5). IC injection at a higher titer
of the vector (1x108 pfu), even without anti-CD40L antibody
treatment, produced more noticeable GFP expression. At day
5, fluorescence was apparent in the corneal endothelium, TM
and the ciliary body. However, the GFP fluorescence dimin-
ished and was barely visible in eyes 43 days after injection
(Figure 6). Again, treatment with anti-CD40L antibody aug-
mented the expression of GFP. In eyes 5 and 43 days after IC
injection of 1x 108 pfu Ad5.CMV-GFP, the TM and corneal
endothelium, and sporadically the lens epithelium and iris were
positive with GFP fluorescence (Figure 6).
As indicated by the in vivo fluorescence grades, IVT in-
jection produced more efficient expression of the injected GFP
vector than IC injection. Fluorescence microscopic observa-
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Figure 4. GFP fluorescence in mouse eyes 35 days following
intravitreal injection.  Images of mouse eyes 35 days after intravitreal
injection of Ad5.CMV-GFP at 1x107 pfu (left panels) or 108 pfu (right
panels) with (upper panels) or without (lower panels) anti-CD40L
treatment. The eyes from mice treated with anti-CD40L antibody
still expressed high level of GFP; their fluorescence grades were be-
tween 2 and 3. In contrast, eyes from mice without anti-CD40L treat-
ment had minimal fluorescence with grades of 1 or below.
Figure 3. GFP fluorescence in mouse eyes six days following
intravitreal injection.  Images of mouse eyes six days after intravitreal
injection of Ad5.CMV-GFP at 1x107 pfu (left panels) or 108 pfu (right
panels) with (upper panels) or without (lower panels) anti-CD40L
treatment. All eyes were expressing a substantial level of GFP with
fluorescence grades of 2 or 3.
14tion substantiated this conclusion. At day 5 after IVT injec-
tion of 1x107 pfu Ad5.CMV-GFP, with or without anti-CD40L
antibody treatment, significant fluorescence was noted in the
TM, corneal endothelium, and occasionally the iris (Figure
7). With the anti-CD40L treatment, a similar distribution of
fluorescence was still present at day 43, whereas in animals
without anti-CD40L antibody, minimal fluorescence was de-
tected at 43 days after injection (Figure 7). Higher titer of the
vector produced more prominent GFP expression. Thus, five
days after IVT injection of 1x108 pfu, the TM, corneal endot-
helium, and sometimes the iris, lens epithelium and ciliary
body demonstrated fluorescence (Figure 8). Treatment with
anti-CD40L antibody prolonged this expression profile till at
least 43 days after vector injection, while without the anti-
body, fluorescence faded and became faint at day 43 (Figure
8).
Therefore, the histological examination of ocular tissues
after various treatment procedures confirmed the observations
by in vivo fluorescence, in that anti-CD40L antibody treat-
ment increased the intensity of ocular GFP expression after
IC injection and prolonged its duration of expression after IVT
injection. Moreover, the fluorescence microscopic assessments
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Figure 5. Representative fluo-
rescence photomicrographs of
cross-sections of mouse ante-
rior segments treated with
intracameral injection of
Ad.CMV-GFP (1x107 pfu).
The animals were euthanized
at either 5 or 43 days after vec-
tor injection with or without
anti-CD40L antibody treat-
ment. Green fluorescence =
GFP, blue  fluorescence =




tissues, such as those in the
outer nuclear layer and retinal
pigmented epithelium, which
was also observable in non-in-
jected eyes (Data not shown).
Abbreviations: C = cornea; CB
= ciliary body; I = iris; L = lens;
R = retina; TM = trabecular
meshwork.
Figure 6. Representative fluo-
rescence photomicrographs of
cross-sections of mouse ante-









See legend of Figure 5 for ad-
ditional information.
15also supported the notions that expression of GFP depended
on the titers used and that IVT injection produced more effi-
cient expression than IC injection.
DISCUSSION
 We describe in this study that Ad5.CMV-GFP, when deliv-
ered by intraocular (IC or IVT) injection into the eye of the
Balb/cJ mouse, led to GFP expression in the anterior segment
structures. In vivo visual examination of the eyes under UV
illumination and fluorescent microscopic observation of ocu-
lar cross-sections indicated GFP expression in the region of
the TM, as well as other tissues, particularly the corneal en-
dothelial cells, and occasionally the iris epithelium, ciliary
body, and lens epithelium. The intensity and extensiveness of
distribution of GFP expression depended on the viral titer used.
The higher viral titer (1x108 pfu) yielded consistently and sig-
nificantly higher GFP expression than the lower titer (1x107
pfu).
We found that eyes given IVT injections yielded reliably
better GFP expression than those given IC injections, prob-
ably because relatively rapid washout of injected viral vector
following IC injection resulted in a low effective viral con-
centration in the anterior chamber, whereas IVT injection led
to a longer-lasting depot in the vitreous. This finding agrees
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Figure 7. Representative fluo-
rescence photomicrographs of
cross-sections of mouse ante-





sections of mouse anterior seg-
ments treated with intravitreal
injection of Ad5.CMV-GFP
(1x107 pfu). See legend of Fig-
ure 5 for additional informa-
tion.
Figure 8. Representative fluo-
rescence photomicrographs of
cross-sections of mouse ante-





sections of mouse anterior seg-
ments treated with intravitreal
injection of Ad5.CMV-GFP
(1x108 pfu). See legend of Fig-
ure 5 for additional informa-
tion.
16with our experience that IVT injection of adenoviral vectors
encoding various transgenes produces more pronounced ex-
pression in the TM and other cells in the anterior segment
than those induced by IC injections (unpublished observations).
Thus, IVT injection of adenovirus containing specific myocilin
mutants generated significant ocular hypertension in the mouse
[4]. Interestingly, even though the vitreous is in close proxim-
ity to the inner retina, we could not detect GFP fluorescence
in retinal tissues after IVT injection of Ad5.CMV-GFP. Oth-
ers have reported that IVT injection of adenoviral vectors pro-
duced transgene expression in the retina. For example, DiPolo
et al. [20] demonstrated adenoviral vector-induced expression
of brain-derived neurotrophic factor in Müller cells. The dis-
crepancy between these results and the current data are likely
due to the lower sensitivity of fluorescence as a detection means
compared to methods such as immunohistochemistry. Regard-
less, our findings suggest that adenoviral vectors have a lower
tropism for cells in the inner retina compared to cells in the
TM. Our results are broadly in keeping with those of Budenz
et al. [7], who also compared the expression profile of IVT
and IC injections of adenovirus encoding LacZ in mice.
Similar to previously published reports [7,8], our aden-
ovirus-mediated transgene expression in the mouse eye was
transient, most probably a result of an immune response gen-
erated against viral proteins [8,11,12]. We reduced this short-
coming by immunomodulation; treating the animals with the
anti-CD40L antibody, which clearly increased the expression
of GFP after IC injection, and significantly prolonged GFP
expression after IVT injection to more than six weeks. In fact,
our most recent data suggest that ocular transgene expression
could be lengthened to at least 12 weeks by this antibody (un-
published observations). These observations concur with prior
findings that treatment of mouse with this antibody signifi-
cantly extended the duration of adenoviral transgene expres-
sion in the liver [17-19].
Even though the anti-CD40L antibody is an
immunomodulating agent, the treated animals did not exhibit
any signs of infection or compromised health. In all respects
they appeared to be completely normal and healthy over the
entire course of the experiment, showing no noticeable alter-
ations in behavior or food or water consumption. The lack of
general untoward effects of the anti-CD40L antibody is con-
sistent with its relatively specific suppression of the CD4+ T-
cell-assisted but B-cell-mediated humoral responses normally
mounted against adenovirus, without having a large number
of other adjunctive actions [13-15]. Indeed, anti-CD40L anti-
body has been administered in mice [17-19,21], rats [22], ba-
boons [23,24], and monkeys [25-27] with minimal undesir-
able consequences.
Therefore, treatment with anti-CD40L antibody represents
a practical and convenient method to improve and prolong
adenoviral transgene expression in the anterior segment of the
mouse eye. Hoffman et al. [8] were similarly successful in
lengthening the duration of ocular expression by injecting the
adenovirus into immunodeficient (nu/nu) CD-1 mice. None-
theless, using the nu/nu CD-1 mouse may not be a practical
solution for many ophthalmological studies. The same re-
searchers also demonstrated that CTLA4Ig, an immunoglo-
bulin shown to block the interaction of CD80 and CD86 ligands
on antigen-presenting cells with CTLA4 receptors on T-cells,
appeared to stabilize the expression of adenovirus in the TM
[8]. The effect of this treatment, however, was not significantly
different from that of treatment with a control immunoglobu-
lin.
The extension of adenoviral transgene expression in tis-
sues of the anterior segment, such as the TM, is an important
accomplishment. Other vector systems have been used to de-
liver genes to this region in various animals, for example,
adeno-associated virus [6], herpes simplex virus [28,29],
lentivirus [30,31], and liposomes [32]. Some of these meth-
ods, such as adeno-associated virus [6] and liposomes [32],
seemed ineffective. Herpes simplex viral vectors were capable
of efficient gene delivery to structures in the anterior segment.
However, in the reported studies, expression of the encoded
gene lasted only 10 days [28,29]. The exact mechanism of
this transience remains unknown, but a promoter shutoff may
be involved. Lentiviral vectors were successfully applied to
deliver genes to the TM [30,31]. An important advantage of
these vectors is their ability to integrate into the host cell ge-
nome even in slowly dividing or non-dividing cells, and to
induce long-term transgene expression. Nevertheless, a key
disadvantage of this approach is the potential for insertional
mutagenesis, which, albeit uncommon, can present consider-
able challenges to data analysis and interpretation. Hence,
adenoviral vectors still serve a vital function in gene delivery
to the anterior segment in various ophthalmological studies,
particularly those related to glaucoma research. Indeed, among
all the different vectors, it is one of the most popular and has
been productively used to introduce transgenes into the TM
of mice [7,8], rats [33], rabbits [34], dogs [35], and monkeys
[36], Our method of immunomodulation significantly improves
its expression duration and overcomes the major limitation of
this gene delivery system.
In summary, we found that GFP can be introduced into
the anterior segment of the Balb/c mouse via a single IVT or
IC injection of Ad5.CMV-GFP. Appropriate titers for this ad-
enoviral vector appeared to be between 1x107 and 1x108 pfu,
and IVT injection was the better method of delivery. GFP was
expressed in the TM, corneal endothelium, and to some ex-
tent other anterior segment tissues. Immunomodulation of the
animals by intraperitoneal injection of anti-CD40L antibody
enhanced both the time and intensity of GFP expression.
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